Literature DB >> 15041072

Selenium and selenomethionine levels in prostate cancer patients.

David W Nyman1, M Suzanne Stratton, Michael J Kopplin, Bruce L Dalkin, Raymond B Nagle, A Jay Gandolfi.   

Abstract

OBJECTIVE: Selenium (Se) and selenomethionine (Se-Met) have been identified as potential chemopreventive agents of prostate cancer. Using an assay for the speciation (separation and identification) and quantification of selenoamino acids, Se-Met was profiled in serum and prostate tissue from prostate cancer patients. Total Se was measured also.
METHODS: Serum and prostate tissue samples were analyzed using high performance liquid chromatography ion channel plasma-mass spectrometry (HPLC ICP-MS). Samples were provided by 25 subjects undergoing radical prostatectomy for the treatment of prostate cancer.
RESULTS: The mean serum Se-Met concentration was 59.4 +/- 19.5 ng/ml. Mean total serum Se levels were 133.8 +/- 29.2 ng/ml. Total Se levels in paired samples from the transitional and peripheral zones of the prostate were also compared. Total mean Se levels in peripheral zone tissue was higher than in transitional zone tissue (0.432 +/- 0.212 microg/g versus 0.293 +/- 0.172 microg/g, P = 0.01). Se-Met was detected in the majority of prostate tissues.
CONCLUSION: This group of prostate cancer patients had total Se levels in serum and in prostate tissue in a range expected for normal Se intake. There was a significantly higher total Se level found in peripheral versus transitional zone tissues. This is the first time that Se-Met has been detected in prostate tissue.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15041072     DOI: 10.1016/j.cdp.2003.11.002

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  7 in total

1.  Expression and potential mechanism of metabolism-related genes and CRLS1 in non-small cell lung cancer.

Authors:  Hai-Ming Feng; Ye Zhao; Jian-Ping Zhang; Jian-Hua Zhang; Peng Jiang; Bin Li; Cheng Wang
Journal:  Oncol Lett       Date:  2017-12-12       Impact factor: 2.967

2.  Differential effects of selenium on benign and malignant prostate epithelial cells: stimulation of LNCaP cell growth by noncytotoxic, low selenite concentrations.

Authors:  Nur Ozten Kandaş; Carla Randolph; Maarten C Bosland
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

3.  Correlation between selenium concentrations and glutathione peroxidase activity in serum and human prostate tissue.

Authors:  Yumie Takata; J Steven Morris; Irena B King; Alan R Kristal; Daniel W Lin; Ulrike Peters
Journal:  Prostate       Date:  2009-11-01       Impact factor: 4.104

4.  Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells.

Authors:  Jeong-In Lee; Hui Nian; Arthur J L Cooper; Raghu Sinha; Jenny Dai; William H Bisson; Roderick H Dashwood; John T Pinto
Journal:  Cancer Prev Res (Phila)       Date:  2009-07

5.  Age-Related Changes in Zinc, Copper and Selenium Levels in the Human Prostate.

Authors:  Adam Daragó; Michał Klimczak; Joanna Stragierowicz; Mateusz Jobczyk; Anna Kilanowicz
Journal:  Nutrients       Date:  2021-04-21       Impact factor: 5.717

6.  Gene expression and biological pathways in tissue of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation.

Authors:  Mark Jesus M Magbanua; Ritu Roy; Eduardo V Sosa; Vivian Weinberg; Scott Federman; Michael D Mattie; Millie Hughes-Fulford; Jeff Simko; Katsuto Shinohara; Christopher M Haqq; Peter R Carroll; June M Chan
Journal:  PLoS One       Date:  2011-09-01       Impact factor: 3.240

7.  A Testosterone Metabolite 19-Hydroxyandrostenedione Induces Neuroendocrine Trans-Differentiation of Prostate Cancer Cells via an Ectopic Olfactory Receptor.

Authors:  Tatjana Abaffy; James R Bain; Michael J Muehlbauer; Ivan Spasojevic; Shweta Lodha; Elisa Bruguera; Sara K O'Neal; So Young Kim; Hiroaki Matsunami
Journal:  Front Oncol       Date:  2018-05-28       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.